Compare VNRX & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VNRX | RAND |
|---|---|---|
| Founded | N/A | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.2M | 41.2M |
| IPO Year | N/A | N/A |
| Metric | VNRX | RAND |
|---|---|---|
| Price | $0.28 | $15.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $3.17 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 3.3K |
| Earning Date | 11-13-2025 | 11-07-2025 |
| Dividend Yield | N/A | ★ 7.73% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,472,007.00 | ★ $7,327,287.00 |
| Revenue This Year | $55.33 | N/A |
| Revenue Next Year | $493.79 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.48 | N/A |
| 52 Week Low | $0.27 | $13.25 |
| 52 Week High | $0.94 | $31.89 |
| Indicator | VNRX | RAND |
|---|---|---|
| Relative Strength Index (RSI) | 32.86 | 71.10 |
| Support Level | $0.28 | $13.95 |
| Resistance Level | $0.34 | $15.49 |
| Average True Range (ATR) | 0.03 | 0.46 |
| MACD | 0.00 | 0.23 |
| Stochastic Oscillator | 11.30 | 100.00 |
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.